https://www.nature.com/articles/d41586-023-02890-1 Skip to main content Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Advertisement Nature * View all journals * Search * Log in * Explore content * About the journal * Publish with us * Subscribe * Sign up for alerts * RSS feed 1. nature 2. news 3. article * NEWS * 14 September 2023 Life-changing cystic fibrosis treatment wins US$3-million Breakthrough Prize Trio of scientists who developed the combination drug Trikafta are among the winners of five major awards in life sciences, physics and mathematics. * Zeeya Merali 1. Zeeya Merali View author publications You can also search for this author in PubMed Google Scholar * Twitter * Facebook * Email You have full access to this article via your institution. Download PDF Left to Right: Negulescu, Hadida and Vangoor headshots. Paul Negulescu, Sabine Hadida and Fredrick Van Goor (left to right) developed a combination treatment that targets a malformed protein in people with cystic fibrosis.Credit: Vertex Pharmaceuticals The triple-drug combination Trikafta has given a new lease of life to 90% of people with cystic fibrosis, an inherited disorder that affects the lungs and other organs. Now, the trio of researchers who spearheaded its development has won one of this year's US$3-million Breakthrough prizes -- the most lucrative awards in science. Sabine Hadida, Paul Negulescu and Fredrick Van Goor at Vertex Pharmaceuticals in San Diego, California, developed the treatment by combining different drugs that help a faulty protein to function. "The development of Trikafta has been one of the most phenomenal and outstanding achievements of biomedical research in the last 30 years," says geneticist and physician Francis Collins at the US National Human Genome Research Institute (NHGRI) in Bethesda, Maryland, who co-discovered the gene for cystic fibrosis in 1989^1. The award was one of five Breakthrough prizes -- awarded for achievements in life sciences, physics and mathematics -- announced on 14 September. Life-changing treatment Cystic fibrosis affects around 100,000 people worldwide, and for many years was considered a life-limiting condition. However, a study this year projected that treatment with drugs such as Trikafta (comprising elexacaftor, tezacaftor and ivacaftor) -- approved by the US Food and Drug Administration in 2019 -- can increase life expectancy from around 30 to more than 80 years^2. "I hear almost every day from people who were really in trouble, with cystic fibrosis severely beginning to affect their chance of survival," says Collins. "Now, after going on Trikafta, they are back at work and thinking about what they might want to do for retirement." [d41586-023] Cystic fibrosis drugs target the malformed proteins at the root of the disease The disease is caused by mutations in the gene that makes the cystic fibrosis transmembrane conductance regulator protein (CFTR), which ordinarily spans the membrane of cells that line several organs and is involved in the production of mucus, sweat and other fluids. In people with cystic fibrosis, these proteins are misfolded and don't function correctly. This causes a build-up of unusually thick secretions, including mucus in the lungs, leading to serious health issues. Once the CFTR gene had been identified, most efforts focused on ways to modify the gene to treat the disease, with little success. The team led by Hadida, Negulescu and Van Goor instead searched for a drug combination to coax the misfolded proteins into functioning correctly. The three drugs in Trikafta work together: two help to deliver more CFTR to the cell surface and the third enables the protein to work better once it is there^3. "There was a lot of scepticism that this could be done," Hadida recalls. "But the patient community was cheering for us." The drug-discovery process required a marathon effort, testing the effects of more than one million compounds on isolated human lung cells to identify candidate drugs for clinical trials. Hadida says she feels "very excited, honoured and surprised" by the award, adding that credit should be shared by the company, people with cystic fibrosis and their families. Genetic links A second life-sciences prize was awarded for the independent discovery of two genes associated with the risk of developing Parkinson's disease: GBA1^4, identified by geneticist Ellen Sidransky at the NHGRI, and LRRK2^5^,^6 by neurogeneticist Andrew Singleton at the US National Institute on Aging in Bethesda and neuroscientist Thomas Gasser at the University of Tubingen, Germany. Sidransky describes being "blown away" after learning of her award, especially because she didn't set out to study Parkinson's disease. Originally a paediatrician, she moved to researching the rare hereditary disorder Gaucher disease, in which fatty substances build up in various organs because of a mutation in the GBA1 gene. When talking to people with the condition, she realized that many had relatives with Parkinson's disease, allowing her to connect the dots. "I want to be a cheerleader for research into rare diseases," Sidransky says. "This is a good example where a study can lead to insights for the wider population." [d41586-023] Last-resort cancer therapy holds back disease for more than a decade Njideka Okubadejo, a neurologist at the University of Lagos in Nigeria, welcomes the award announcement. Okubadejo, Singleton -- who leads the Global Parkinson's Genetics Program -- and others have identified a new genetic risk factor for Parkinson's disease in the GBA1 gene in people with African ancestry that is rarely seen in those of European descent^7. "The next step is to find a biological mechanism by which the gene causes the disease," Okubadejo says. "Then you can build upon that to reduce the likelihood of the disease occurring." A third life-sciences prize was awarded to immunologists Carl June at the University of Pennsylvania in Philadelphia, and Michel Sadelain at the Memorial Sloan Kettering Cancer Center in New York City for developing a CAR-T-cell immunotherapy treatment for leukaemia that stimulates patients' own immune T cells to target and kill cancer cells^8^,^9. This therapy can lead to long-lasting remission of some cancers^10. Theories of everything Other Breakthrough winners include John Cardy at the University of Oxford, UK, and Alexander Zamolodchikov at Stony Brook University in New York, who share the physics prize for a body of work on 'conformal field theories' -- a family of mathematical theories that applies to a huge range of physical phenomena, from boiling water to the surface of black holes. In most situations, the equations are extremely tough to solve exactly, but Zamolodchikov discovered a solution in 2D in the 1980s^11, and Cardy built on these results by proposing that the result could be generalized to 4D^12 and by applying conformal field theories to better understand phase transitions in materials. Cardy, who was "over the moon" to learn about the prize, recalls learning about Zamolodchikov's work from two Russian scientists at a conference. "Hardly anybody in the West understood what they were talking about," Cardy says. "But I came away convinced I had to start working on it." [d41586-023] AlphaFold developers win US$3-million Breakthrough Prize "Cardy and Zamolodchikov truly are giants of conformal field theories," says David Tong, a physicist at the University of Cambridge, UK. "There are physicists around the world who are working on extraordinarily different problems, and yet they have a common language through the work of Cardy, Zamolodchikov and others." Simon Brendle at Columbia University in New York City has won the mathematics Breakthrough prize for his contributions to differential geometry -- the study of curves, surfaces and spaces. Among other achievements, Brendle proved 'Lawson's conjecture' concerning the minimal surface of a '3-sphere', which is the surface of a hypothetical 4D sphere^13. The Breakthrough prizes were founded in 2012 and are sponsored by Yuri Milner, a Russian-Israeli billionaire, and other Internet entrepreneurs, including Meta's chief executive Mark Zuckerberg. doi: https://doi.org/10.1038/d41586-023-02890-1 References 1. Riordan, J. R. et al. Science 245, 1066-1073 (1989). Article PubMed Google Scholar 2. Lopez, A., Daly, D., Vega-Hernandez, G., MacGregor, G. & Rubin, J. L. J. Cyst. Fibros. 22, 607-614 (2023). Article PubMed Google Scholar 3. Keating, D. et al. N. Engl. J. Med. 379, 1612-1620 (2018). Article PubMed Google Scholar 4. Sidransky, E. et al. N. Engl. J. Med. 361, 1651-1661 (2009). Article PubMed Google Scholar 5. Gilks, W. P. et al. Lancet 365, 415-416 (2005). Article PubMed Google Scholar 6. Zimprich, A. et al. Neuron 44, 601-607 (2004). Article PubMed Google Scholar 7. Rizig, M. et al. Lancet Neurol. https://doi.org/10.1016/ S1474-4422(23)00283-1 (2023). Article PubMed Google Scholar 8. Brentjens, R. J. et al. Nature Med. 9, 279-286 (2003). Article PubMed Google Scholar 9. Kalos, M. et al. Sci. Transl. Med. 3, 95ra73 (2011). Article PubMed Google Scholar 10. Melenhorst, J. J. et al. Nature 602, 503-509 (2022). Article PubMed Google Scholar 11. Belavin, A. A., Polyakov, A. M. & Zamolodchikov, A. B. Nucl. Phys. B 241, 333-380 (1984). Article Google Scholar 12. Cardy, J. L. Phys. Lett. B 215, 749-752 (1988). Article Google Scholar 13. Brendle, S. Acta. Math. 211, 177-190 (2013). Article Google Scholar Download references Reprints and Permissions Related Articles * [d41586-023] Cystic fibrosis drugs target the malformed proteins at the root of the disease * [d41586-023] Last-resort cancer therapy holds back disease for more than a decade * [d41586-023] AlphaFold developers win US$3-million Breakthrough Prize * [d41586-023] COVID advances win US$3-million Breakthrough prizes * [d41586-023] Discoverer of neural circuits for parenting wins US$3-million Breakthrough Prize * [d41586-023] Pulsar discoverer Jocelyn Bell Burnell wins $3-million Breakthrough Prize Subjects * Mathematics and computing * Physics * Drug discovery * Diseases Latest on: Mathematics and computing How my broken elbow made the ableism of computer programming personal How my broken elbow made the ableism of computer programming personal Career Column 14 SEP 23 A test of artificial intelligence A test of artificial intelligence Outlook 14 SEP 23 Why Japan is building its own version of ChatGPT Why Japan is building its own version of ChatGPT News 14 SEP 23 Physics Cardiac cycle inspires optimized pipe flow Cardiac cycle inspires optimized pipe flow News & Views 06 SEP 23 Why a blockbuster superconductivity claim met a wall of scepticism Why a blockbuster superconductivity claim met a wall of scepticism News Feature 06 SEP 23 Adsorbate motors for unidirectional translation and transport Adsorbate motors for unidirectional translation and transport Article 06 SEP 23 Drug discovery Psychedelic drug MDMA moves closer to US approval following success in PTSD trial Psychedelic drug MDMA moves closer to US approval following success in PTSD trial News 14 SEP 23 Four ways research aims to outwit cancer's evasion tactics Four ways research aims to outwit cancer's evasion tactics Nature Index 06 SEP 23 CD300ld on neutrophils is required for tumour-driven immune suppression CD300ld on neutrophils is required for tumour-driven immune suppression Article 06 SEP 23 Nature Careers Jobs * Senior Scientists Sanofi Institute for Biomedical Research (SIBR) is seeking multiple highly motivated individuals with doctoral degrees to join our institute locate... Suzhou Sanofi Institute for Biomedical Research [] * Lab Head, Degrader Technologies Sanofi Institute for Biomedical Research (SIBR) is seeking a highly motivated individual with extensive knowledge and research experience in degrad... Suzhou, Jiangsu, China Sanofi Institute for Biomedical Research [] * Tenure-track or Senior Tenured Professor Tenured or Tenure Track Professor Position in the Department of Genomics and Computational Biology at UMass Chan Medical School. Massachusetts (US) UMass Chan Medical School Genomics and Computational Biology * Faculty Positions in Data Science, Artificial Intelligence and Machine Learning The institute invites researchers working actively in the areas of computational statistics, machine learning and related areas. Hyderabad, Andhra Pradesh (IN) Tata Institute of Fundamental Research, Hyderabad [] * ATLAS - Joint PhD Program from BioNTech and TRON with a focus on translational medicine 9 PhD positions for ATLAS, the joint PhD Program from BioNTech and TRON with a focus on translational medicine. Mainz, Rheinland-Pfalz (DE) Translational Oncology (TRON) Mainz [] You have full access to this article via your institution. Download PDF Related Articles * [d41586-023] Cystic fibrosis drugs target the malformed proteins at the root of the disease * [d41586-023] Last-resort cancer therapy holds back disease for more than a decade * [d41586-023] AlphaFold developers win US$3-million Breakthrough Prize * [d41586-023] COVID advances win US$3-million Breakthrough prizes * [d41586-023] Discoverer of neural circuits for parenting wins US$3-million Breakthrough Prize * [d41586-023] Pulsar discoverer Jocelyn Bell Burnell wins $3-million Breakthrough Prize Subjects * Mathematics and computing * Physics * Drug discovery * Diseases Advertisement Sign up to Nature Briefing An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday. Email address [ ] [ ] Yes! Sign me up to receive the daily Nature Briefing email. I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Sign up * Close Nature Briefing Sign up for the Nature Briefing newsletter -- what matters in science, free to your inbox daily. Email address [ ] Sign up [ ] I agree my information will be processed in accordance with the Nature and Springer Nature Limited Privacy Policy. Close Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing Explore content * Research articles * News * Opinion * Research Analysis * Careers * Books & Culture * Podcasts * Videos * Current issue * Browse issues * Collections * Subjects * Follow us on Facebook * Follow us on Twitter * Subscribe * Sign up for alerts * RSS feed About the journal * Journal Staff * About the Editors * Journal Information * Our publishing models * Editorial Values Statement * Journal Metrics * Awards * Contact * Editorial policies * History of Nature * Send a news tip Publish with us * For Authors * For Referees * Language editing services * Submit manuscript Search Search articles by subject, keyword or author [ ] Show results from [All journals] Search Advanced search Quick links * Explore articles by subject * Find a job * Guide to authors * Editorial policies Nature (Nature) ISSN 1476-4687 (online) ISSN 0028-0836 (print) nature.com sitemap About Nature Portfolio * About us * Press releases * Press office * Contact us Discover content * Journals A-Z * Articles by subject * Nano * Protocol Exchange * Nature Index Publishing policies * Nature portfolio policies * Open access Author & Researcher services * Reprints & permissions * Research data * Language editing * Scientific editing * Nature Masterclasses * Live Expert Trainer-led workshops * Research Solutions Libraries & institutions * Librarian service & tools * Librarian portal * Open research * Recommend to library Advertising & partnerships * Advertising * Partnerships & Services * Media kits * Branded content Career development * Nature Careers * Nature Conferences * Nature events Regional websites * Nature Africa * Nature China * Nature India * Nature Italy * Nature Japan * Nature Korea * Nature Middle East * Privacy Policy * Use of cookies * Your privacy choices/Manage cookies * Legal notice * Accessibility statement * Terms & Conditions * Your US state privacy rights Springer Nature (c) 2023 Springer Nature Limited